GSK: contracts with Washington for Sotrovimab

(CercleFinance.com) - GlaxoSmithKline (GSK) and Vir Biotechnology have announced contracts with the US government totalling approximately 1 billion dollars for doses of sotrovimab, their investigational monoclonal antibody for the early treatment of Covid-19.


The FDA granted the product emergency approval in May. GSK will provide these doses by 17 December. In addition to those to be provided this year,

Washington will be able to purchase additional doses through to March 2022.

With the contracts announced today, GSK and Vir have entered into binding agreements to sell over 750,000 doses of sotrovimab worldwide, with additional doses reserved through other agreements.


Copyright (c) 2021 CercleFinance.com. All rights reserved.